Drug Trial Radar · NCT05039866
Long-Term Follow-up of Subjects Who Were Treated With ST-920
Last checked: Nov 19, 2026Latest source record: Aug 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
32
Actual
Start
Aug 16, 2021
Primary completion
Mar 2029
Study completion Mar 2039
Sponsor
- Lead sponsor
- Sangamo TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Sep 10, 2021
Design
- Study type
- Observational
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Long-term follow-up of subjects who received ST-920 in a previous trial (ST-920-201) and completed at least 52 weeks post-infusion follow-up in their primary protocol. Enrolled subjects will be followed for a total of up to 5 years following ST-920 infusion.
Conditions
- Fabry Disease
- Fabry Disease, Cardiac Variant
Interventions
ST-920Biological
No study drug is administered in this study. Subjects who received ST-920 in a separate parent trial will be evaluated in this trial for long-term safety.
Primary outcomes
What the sponsor says the trial is designed to measure.
- To evaluate long-term safety of ST-920Time frame: 4 years
Locations
13 sites in 5 countries. Site status is shown where the registry gives one.
University of California, Irvine
Irvine, California
University of South Florida
Tampa, Florida
Emory University School of Medicine
Atlanta, Georgia
University of Iowa Hospital and Clinics
Iowa City, Iowa
University of Minnesota Medical Center
Minneapolis, Minnesota
Mt. Sinai Hospital
New York, New York
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio
Lysosomal & Rare Disorders Research & Treatment Center (LDRTC)
Fairfax, Virginia
The Royal Melbourne Hospital
Parkville, Victoria, Australia
M.A.G.I.C. Clinic Ltd.
Calgary, Alberta, Canada
University Hospital of Würzburg
Würzburg, Germany
Addenbrooke's Hospital
Cambridge, United Kingdom
Royal Free Hospital
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.